Haemonetics Acquires Vivasure Medical for €100 Million Upfront Payment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: NASDAQ.COM
- Acquisition Deal: Haemonetics has acquired Ireland-based Vivasure Medical for an upfront cash payment of €100 million, with approximately €52 million net of prior investments, indicating the company's commitment to enhancing its competitive edge in medical technology.
- Technological Innovation: The PerQseal Elite system developed by Vivasure has received CE Mark approval and a Premarket Approval application submitted to the FDA, providing a sutureless, fully absorbable solution that is expected to enhance Haemonetics' product offerings in the cardiovascular surgery market.
- Funding Source: The acquisition is funded through Haemonetics' available cash, demonstrating the company's financial stability and confidence in future growth while securing funding for its technological expansion.
- Market Reaction: Following the acquisition announcement, Haemonetics' stock rose by 1.12% to $84.98 on the New York Stock Exchange, reflecting positive market sentiment regarding the acquisition and its potential for business growth.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
